Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high‐risk sarcomas
Open Access
- 15 March 2006
- Vol. 106 (8), 1846-1856
- https://doi.org/10.1002/cncr.21810
Abstract
BACKGROUND Intensified chemotherapy may improve the outcome of patients with high-risk pediatric sarcomas. Vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide are highly effective against pediatric sarcomas. The authors investigated the feasibility of administering these agents concomitantly within a defined period. METHODS In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12). Three additional cycles of VACIE were then given. After delayed hematologic recovery in the first 11 patients, the protocol was modified (HIRISA2) to delay local control therapy until after 5 cycles of VACIE (to be completed within 18 weeks). Patients who responded to the protocols were eligible for myeloablative consolidation with autologous stem cell support. RESULTS Eleven of 24 patients (median age, 14.9 years) had Ewing sarcoma family of tumors, 9 patients had rhabdomyosarcoma, and 4 patients had unresectable desmoplastic small round cell tumors. Seven of 13 patients on HIRISA2, but none of 11 patients on HIRISA1, completed therapy within the specified time. Reversible Grade 4 myelosuppression was the most common toxicity. Major nonhematologic toxic effects were mucositis, nutritional impairment, hypotension, and peripheral neuropathy. Three patients died of toxicity. The 5-year survival and 5-year event-free survival estimates both were 45.8% ± 11.2%. CONCLUSIONS The feasibility of administering intensive chemotherapy regimens like VACIE was dependent in part on the timing of local control therapy. This regimen was associated with significant toxicity. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 35 references indexed in Scilit:
- European Intergroup Studies (MMT4-89 and MMT4-91) on Childhood Metastatic Rhabdomyosarcoma: Final Results and Analysis of Prognostic FactorsJournal of Clinical Oncology, 2004
- Cyclophosphamide Dose Intensification during Induction Therapy for Intermediate-Risk Pediatric Rhabdomyosarcoma Is Feasible but Does Not Improve OutcomeClinical Cancer Research, 2004
- Treatment of Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor of Bone: Evaluation of Combination Ifosfamide and Etoposide—A Children's Cancer Group and Pediatric Oncology Group StudyJournal of Clinical Oncology, 2004
- Efficacy of combined surgery and irradiation for localized Ewings sarcoma family of tumorsPediatric Blood & Cancer, 2004
- Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of BoneNew England Journal of Medicine, 2003
- Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomasCancer, 2002
- Clinical Features and Outcome of Initially Unresected Nonmetastatic Pediatric Nonrhabdomyosarcoma Soft Tissue SarcomaJournal of Clinical Oncology, 2002
- Treatment of Children with Peripheral Primitive Neuroectodermal Tumor or Extraosseous Ewingʼs Tumor with Ewingʼs-Directed TherapyJournal of Pediatric Hematology/Oncology, 1998
- Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: A retrospective european multi‐center analysisMedical and Pediatric Oncology, 1992
- Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacologyPharmacology & Therapeutics, 1983